Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $802.52M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.89% Avg Daily Range (30 D): $0.05 | 3.20% Avg Daily Range (90 D): $0.05 | 3.64% Institutional Daily Volume Avg Daily Volume: 2.76M Avg Daily Volume (30 D): 7.81M Avg Daily Volume (90 D): 10.18M Trade Size Avg Trade Size (Sh.): 343 Avg Trade Size (Sh.) (30 D): 491 Avg Trade Size (Sh.) (90 D): 511 Institutional Trades Total Inst.Trades: 2,640 Avg Inst. Trade: $1.87M Avg Inst. Trade (30 D): $1.27M Avg Inst. Trade (90 D): $1.37M Avg Inst. Trade Volume: .61M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.36M Avg Closing Trade (30 D): $1.25M Avg Closing Trade (90 D): $1.43M Avg Closing Volume: 812.4K     News May 12, 2025 @ 1:54 PM GERN Investors are Reminded of an Opportunity to L... Source: Prnewswire May 11, 2025 @ 12:17 PM Faruqi & Faruqi Reminds Geron Investors of the Pen... Source: N/A May 9, 2025 @ 1:00 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp May 9, 2025 @ 12:00 PM INVESTOR ALERT: Pomerantz Law Firm Announces the F... Source: N/A May 7, 2025 @ 8:35 PM Why Geron Stock Crept Higher Today Source: Eric Volkman Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.21 $-.03 $-.04 Diluted EPS $-.21 $-.03 $-.04 Revenue $ 116.29M $ 39.6M $ 47.54M Gross Profit $ $ $ Net Income / Loss $ -139.02M $ -19.84M $ -25.35M Operating Income / Loss $ -134.3M $ -16.7M $ -20.05M Cost of Revenue $ $ $ Net Cash Flow $ -105.26M $ 4.73M $ 18.71M PE Ratio